Systemic Sclerosis

You have full text access to this OnlineOpen article

The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France

  1. Eric Hachulla1,†,*,
  2. Pascal de Groote2,
  3. Virginie Gressin3,‡,
  4. Jean Sibilia4,§,
  5. Elisabeth Diot5,
  6. Patrick Carpentier6,¶,
  7. Luc Mouthon7,‖,
  8. Pierre-Yves Hatron1,††,
  9. Patrick Jego8,
  10. Yannick Allanore7,‡‡,
  11. Kiet Phong Tiev9,
  12. Christian Agard10,
  13. Anne Cosnes11,
  14. Daniela Cirstea12,
  15. Joël Constans13,
  16. Dominique Farge14,
  17. Jean-François Viallard15,
  18. Jean-Robert Harle16,
  19. Frédéric Patat17,
  20. Bernard Imbert6,
  21. André Kahan7,§§,
  22. Jean Cabane9,
  23. Pierre Clerson18,
  24. Loïc Guillevin7,¶¶,
  25. Marc Humbert19

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24525

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1831–1839, June 2009

Additional Information

How to Cite

Hachulla, E., de Groote, P., Gressin, V., Sibilia, J., Diot, E., Carpentier, P., Mouthon, L., Hatron, P.-Y., Jego, P., Allanore, Y., Tiev, K. P., Agard, C., Cosnes, A., Cirstea, D., Constans, J., Farge, D., Viallard, J.-F., Harle, J.-R., Patat, F., Imbert, B., Kahan, A., Cabane, J., Clerson, P., Guillevin, L. and Humbert, M. (2009), The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis & Rheumatism, 60: 1831–1839. doi: 10.1002/art.24525

Author Information

  1. 1

    Hôpital Claude Huriez, Lille, France

  2. 2

    Centre Hospitalier Régional Universitaire, Lille, France

  3. 3

    Actelion Pharmaceuticals France, Paris, France

  4. 4

    Hôpital de Hautepierre, Strasbourg, France

  5. 5

    Hôpital Bretonneau, Tours, France

  6. 6

    Hôpital Nord, Grenoble, France

  7. 7

    Hôpital Cochin, Paris, France

  8. 8

    Hôpital Sud, Rennes, France

  9. 9

    Hôpital St. Antoine, Paris, France

  10. 10

    Hôtel Dieu, Nantes, France

  11. 11

    Hôpital Henri Mondor, Créteil, France

  12. 12

    Hôpital Central, Nancy, France

  13. 13

    Hôpital St. André, Bordeaux, France

  14. 14

    Hôpital St. Louis, Paris, France

  15. 15

    Hôpital du Haut Lévesque, Pessac, France

  16. 16

    Hôpital de la Conception, Marseilles, France

  17. 17

    Université François Rabelais, Tours, France

  18. 18

    Orgamétrie, Roubaix, France

  19. 19

    Université Paris-Sud 11, and Hôpital Antoine Béclère, Assistance Publique Hôpitaux de Paris, Clamart, France

  1. †

    Dr. Hachulla has received consulting fees, speaking fees, and/or honoraria from Actelion, Pfizer, and GlaxoSmithKline (less than $10,000 each).

  2. ‡

    Dr. Gressin owns stock or stock options in Actelion.

  3. §

    Dr. Sibilia has received speaking fees from Actelion (less than $10,000).

  4. Dr. Carpentier has received honoraria as a member of the Scientific Committee on Scleroderma for Actelion France (less than $10,000).

  5. ‖

    Dr. Mouthon has received consulting fees, speaking fees, and/or honoraria from Actelion and LFB (less than $10,000 each).

  6. ††

    Dr. Hatron has received honoraria from Pierre Fabre Laboratories and Pfizer (less than $10,000 each).

  7. ‡‡

    Dr. Allanore has received consulting fees, speaking fees, and/or honoraria from Actelion and Encysive (less than $10,000 each).

  8. §§

    Dr. Kahan has received consulting fees, speaking fees, and/or honoraria from Actelion (less than $10,000).

  9. ¶¶

    Dr. Guillevin has received speaking fees and honoraria from Actelion (less than $10,000).

*Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille 2, 59037 Lille Cedex, France

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 17 FEB 2009
  4. Manuscript Received: 5 AUG 2008

Funded by

  • Actelion Pharmaceuticals France

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (96K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rebecca L Manno, Laura K Hummers, Aging and scleroderma, Aging Health, 2011, 7, 2, 231

    CrossRef

  2. 2
    James V. Dunne, Julie P. Chou, Mohan Viswanathan, Pearce Wilcox, Simon H. Huang, Cardiac tamponade and large pericardial effusions in systemic sclerosis, Clinical Rheumatology, 2011, 30, 3, 433

    CrossRef

  3. 3
    Richard K. Burt, Francesca Milanetti, Hematopoietic stem cell transplantation for systemic sclerosis, Current Opinion in Rheumatology, 2011, 23, 6, 519

    CrossRef

  4. 4
    E. Hachulla, D. Launay, Hypertension artérielle pulmonaire associée aux connectivites : particularités cliniques et pronostiques, Revue des Maladies Respiratoires Actualités, 2011, 3, S49

    CrossRef

  5. 5
    V. Cottin, Poumon et connectivites, La Revue de Médecine Interne, 2011, 32, S241

    CrossRef

  6. 6
    Christophe Meune, Jérôme Avouac, Paolo Airò, Lorenzo Beretta, Philippe Dieudé, Karim Wahbi, Paola Caramaschi, Kiet Tiev, Susanna Cappelli, Elisabeth Diot, Alessandra Vacca, Jean-Luc Cracowski, Jean Sibilia, André Kahan, Marco Matucci-Cerinic, Yannick Allanore, Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations, Arthritis & Rheumatism, 2011, 63, 9
    Direct Link:
  7. 7
    Michael York, Harrison W. Farber, Pulmonary hypertension, Current Opinion in Rheumatology, 2011, 23, 6, 536

    CrossRef

  8. 8
    Marc Humbert, Azzedine Yaici, Pascal de Groote, David Montani, Olivier Sitbon, David Launay, Virginie Gressin, Loïc Guillevin, Pierre Clerson, Gérald Simonneau, Eric Hachulla, Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival, Arthritis & Rheumatism, 2011, 63, 11
    Direct Link:
  9. 9
    Paola Caramaschi, Alessandra Dalla Gassa, Daniele Prati, Giovanni Barausse, Ilaria Tinazzi, Viviana Ravagnani, Silvia Confente, Domenico Biasi, Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost, Rheumatology International, 2011,

    CrossRef

  10. 10
    Christopher P Denton, Jerome Avouac, Frank Behrens, Daniel E Furst, Ivan Foeldvari, Marc Humbert, Doerte Huscher, Otylia Kowal-Bielecka, Marco Matucci-Cerinic, Peter Nash, Christian F Opitz, David Pittrow, Lewis J Rubin, James R Seibold, Oliver Distler, Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed, Arthritis Research & Therapy, 2011, 13, 3, 114

    CrossRef

  11. 11
    Luis Alberto Ruiz Iturriaga, Adolfo Baloira, Circulación pulmonar: aportaciones del año 2009, Archivos de Bronconeumología, 2010, 46, 38

    CrossRef

  12. 12
    Theodoros Dimitroulas, Georgios Giannakoulas, Klio Papadopoulou, Tilemahos Sfetsios, Haralambos Karvounis, Hariklia Dimitroula, Despina Parcharidou, Georgios Koliakos, Alexandros Garyfallos, Ioannis Styliadis, Loukas Settas, Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis, Clinical Rheumatology, 2010, 29, 9, 957

    CrossRef

  13. 13
    Rejane Maria Oravec, Markus Bredemeier, Claudia Cilene Laurino, Antônio Fernando Furlan Pinotti, Luis Eduardo Paim Rohde, João Carlos Tavares Brenol, Ricardo Machado Xavier, NT-proBNP levels in systemic sclerosis: Association with clinical and laboratory abnormalities, Clinical Biochemistry, 2010, 43, 9, 745

    CrossRef

  14. 14
    E. Hachulla, D. Launay, A. Yaici, A. Berezne, P. de Groote, O. Sitbon, L. Mouthon, L. Guillevin, P. Y. Hatron, G. Simonneau, P. Clerson, M. Humbert, Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome, Rheumatology, 2010, 49, 5, 940

    CrossRef

  15. 15
    Jérôme Pavec, David Launay, Stephen C. Mathai, Paul M. Hassoun, Marc Humbert, Scleroderma Lung Disease, Clinical Reviews in Allergy & Immunology, 2010, 40, 2, 104

    CrossRef

  16. 16
    Theodoros Dimitroulas, Georgios Giannakoulas, Hariklia Dimitroula, Tilemahos Sfetsios, Despina Parcharidou, Haralambos Karvounis, Loukas Settas, Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study, Rheumatology International, 2010, 31, 2, 263

    CrossRef

  17. 17
    Laura K. Hummers, The Current State of Biomarkers in Systemic Sclerosis, Current Rheumatology Reports, 2010, 12, 1, 34

    CrossRef

  18. 18
    D. Launay, O. Sitbon, J. Le Pavec, L. Savale, C. Tcherakian, A. Yaici, L. Achouh, F. Parent, X. Jais, G. Simonneau, M. Humbert, Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil, Rheumatology, 2009, 49, 3, 490

    CrossRef

  19. 19
    Geoff STRANGE, Peter NASH, The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy, International Journal of Rheumatic Diseases, 2009, 12, 3
    Direct Link:
View Full Article (HTML) Get PDF (96K)